Skip to main content
    F

    Fulcrum Therapeutics Inc (FULC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.75
    +0.04 (+1.08%)

    Market Cap: $283.38M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Fulcrum Therapeutics Inc (FULC) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Fulcrum Therapeutics (FULC) has a market cap of $283.38M and an enterprise value of $166.97M. Its share count is up 21.92% from a year earlier. It holds $116.41M more cash than debt, 41.08% of its market cap.

    Total Valuation

    Enterprise value is 41.08% below the market cap, as cash exceeds debt.

    Market Cap$283.38M
    Enterprise Value$166.97M
    Latest price (Nov 17, 2026)$3.75

    Key Dates

    The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 22, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.07% in the quarter ended Sep 30, 2026 and grew 10.58% a year over 2 years.

    Shares Outstanding76.32M
    Shares Change (YoY)+21.92%
    Shares Change (QoQ)+0.07%
    Share Count Growth (2Y CAGR)+10.58%

    Price Statistics

    The stock is down 56.65% over 52 weeks and trades 0.54% above its 50-day average.

    Beta (1Y)0.53
    52-Week Change-56.65%
    1-Month Change+1.35%
    3-Month Change-4.09%
    6-Month Change-36.55%
    5-Year Change-83.24%
    Total Return (1Y)-56.65%
    Total Return (3Y CAGR)-3.32%
    Total Return (5Y CAGR)-26.26%
    Return vs SPY (1Y)-73.02%
    Max Drawdown (1Y)-78.49%
    Max Drawdown (3Y)-79.08%
    Sharpe Ratio (1Y)-0.95
    Correlation with SPY (1Y)0.07
    50-Day Average$3.73
    200-Day Average$5.45
    52-Week Range$2.83 to $15.74
    RSI (14 Days)52.7
    Average Volume (20 Days)1.35M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 36.19x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio36.19x
    Quick Ratio36.19x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -25.28% over the last 12 months, against a 5-year average of -32.06%.

    Return on Equity (ROE)-25.28%
    Return on Assets (ROA)-24.56%
    ROE (5Y Average)-32.06%
    ROA (5Y Average)-28.96%
    ROIC (5Y Average)-19.19%

    Scores

    FULC has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Gross Profit$300.00K
    Operating Income-$88.05M
    Pretax Income-$76.34M
    Net Income-$76.34M
    Reported EPS (TTM)-$0.96

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 97.18% of the $310.81M in total assets.

    Cash and Equivalents$116.41M
    Total Debt$0
    Net Cash$116.41M
    Net Cash Per Share$1.53
    Working Capital$302.21M
    Shareholder Equity$302.03M
    Book Value Per Share$3.96
    Total Assets$310.81M
    Total Liabilities$8.78M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$64.97M
    FCF Per Share-$0.85
    Depreciation and Amortization$3.49M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)+20.38%
    Tangible Book Per Share Growth (2Y CAGR)+20.38%

    Revenue and profit by year

    Dividends and Yields

    FULC does not pay a dividend.

    Buyback Yield-58.89%
    Shareholder Yield-58.89%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About FULC

    What is FULC's market cap?

    Fulcrum Therapeutics has a market cap of $283.38M. Its enterprise value, which adds debt and subtracts cash, is $166.97M.

    How many shares of FULC are outstanding?

    Fulcrum Therapeutics has 76.32M shares outstanding. The count is up 21.92% from a year earlier.

    Does FULC pay a dividend?

    No. Fulcrum Therapeutics does not pay a dividend.

    How much debt does FULC have?

    Fulcrum Therapeutics has $0 of total debt and $116.41M of cash and equivalents, a net cash position of $116.41M.